Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus

Research output: Chapter in Book/Report/Conference proceedingConference contribution

40 Citations (Scopus)

Abstract

Excessive lipid peroxidation is a major factor of accelerated atherosclerosis, observed in patients with systemic lupus erythematosus (SLE). We aimed at the present study to determine the paraoxonase1 (PON1) and arylesterase activities, and lipid-profile in 37 SLE patients and 30 age-/sex-matched controls. Association was analyzed between PON1 activity and SLEDAI, CRP, anti-oxLDL, and antiphospholipid antibody (aPL) levels, steroid dose, and atherothrombotic events. The age of patients was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, SLEDAI 2 (0-15). PON1 and arylesterase activities were measured spectrophotometrically using paraoxon and phenyl acetate as substrates, respectively. Phenotypic distribution of PON1 was determined by dual substrate method. We measured anti-oxLDL and aPL levels by ELISA, the CRP by automated immunoassay. PON1 activity (121.9 ± 65.9 U/mL) was reduced significantly (P <0.001) in SLE as compared to control (188.1 ± 78.9 U/mL), but arylesterase activity was not different. A negative correlation was found between PON1 activity and age. PON1 activity did not correlate with other measured parameters. Reduced PON1 activity associated with clinical atherothrombotic complications (P <0.01). High activity BB phenotypewas not present in SLE. Lipid parameters (TC, LDL-C, HDLC, ApoAI, and ApoB) were within normal range in both groups. Results indicated reduced PON1 activity in lupus patients despite long disease duration and low inflammatory activity, and it was evidenced as a risk for atherosclerotic complications. As the arylesterase activity was normal, further examinations are required to find other mechanisms, such as anti-PON1 antibodies, genetic polymorphisms, and difference in distribution of HDL-subfractions or enzyme abnormalities in HDL remodeling.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages83-91
Number of pages9
Volume1108
DOIs
Publication statusPublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Systemic Lupus Erythematosus
Atherosclerosis
Anti-Idiotypic Antibodies
Antiphospholipid Antibodies
Lipids
Paraoxon
Apolipoproteins B
Genetic Polymorphisms
Substrates
Polymorphism
Immunoassay
Lipid Peroxidation
Reference Values
Enzyme-Linked Immunosorbent Assay
Steroids
arylesterase
Enzymes
oxidized low density lipoprotein

Keywords

  • Antioxidant
  • Atherosclerosis
  • Paraoxonase1
  • SLE

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kiss, E., Seres, I., Tarr, T., Kocsis, Z., Szegedi, G., & Paragh, G. (2007). Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. In Annals of the New York Academy of Sciences (Vol. 1108, pp. 83-91). (Annals of the New York Academy of Sciences; Vol. 1108). https://doi.org/10.1196/annals.1422.009

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. / Kiss, E.; Seres, I.; Tarr, T.; Kocsis, Zsolt; Szegedi, G.; Paragh, G.

Annals of the New York Academy of Sciences. Vol. 1108 2007. p. 83-91 (Annals of the New York Academy of Sciences; Vol. 1108).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Kiss, E, Seres, I, Tarr, T, Kocsis, Z, Szegedi, G & Paragh, G 2007, Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. in Annals of the New York Academy of Sciences. vol. 1108, Annals of the New York Academy of Sciences, vol. 1108, pp. 83-91. https://doi.org/10.1196/annals.1422.009
Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. In Annals of the New York Academy of Sciences. Vol. 1108. 2007. p. 83-91. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1422.009
Kiss, E. ; Seres, I. ; Tarr, T. ; Kocsis, Zsolt ; Szegedi, G. ; Paragh, G. / Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Annals of the New York Academy of Sciences. Vol. 1108 2007. pp. 83-91 (Annals of the New York Academy of Sciences).
@inproceedings{fb02c48d42514130828f6a6a4b1a08d8,
title = "Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus",
abstract = "Excessive lipid peroxidation is a major factor of accelerated atherosclerosis, observed in patients with systemic lupus erythematosus (SLE). We aimed at the present study to determine the paraoxonase1 (PON1) and arylesterase activities, and lipid-profile in 37 SLE patients and 30 age-/sex-matched controls. Association was analyzed between PON1 activity and SLEDAI, CRP, anti-oxLDL, and antiphospholipid antibody (aPL) levels, steroid dose, and atherothrombotic events. The age of patients was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, SLEDAI 2 (0-15). PON1 and arylesterase activities were measured spectrophotometrically using paraoxon and phenyl acetate as substrates, respectively. Phenotypic distribution of PON1 was determined by dual substrate method. We measured anti-oxLDL and aPL levels by ELISA, the CRP by automated immunoassay. PON1 activity (121.9 ± 65.9 U/mL) was reduced significantly (P <0.001) in SLE as compared to control (188.1 ± 78.9 U/mL), but arylesterase activity was not different. A negative correlation was found between PON1 activity and age. PON1 activity did not correlate with other measured parameters. Reduced PON1 activity associated with clinical atherothrombotic complications (P <0.01). High activity BB phenotypewas not present in SLE. Lipid parameters (TC, LDL-C, HDLC, ApoAI, and ApoB) were within normal range in both groups. Results indicated reduced PON1 activity in lupus patients despite long disease duration and low inflammatory activity, and it was evidenced as a risk for atherosclerotic complications. As the arylesterase activity was normal, further examinations are required to find other mechanisms, such as anti-PON1 antibodies, genetic polymorphisms, and difference in distribution of HDL-subfractions or enzyme abnormalities in HDL remodeling.",
keywords = "Antioxidant, Atherosclerosis, Paraoxonase1, SLE",
author = "E. Kiss and I. Seres and T. Tarr and Zsolt Kocsis and G. Szegedi and G. Paragh",
year = "2007",
month = "6",
doi = "10.1196/annals.1422.009",
language = "English",
isbn = "157331708X",
volume = "1108",
series = "Annals of the New York Academy of Sciences",
pages = "83--91",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus

AU - Kiss, E.

AU - Seres, I.

AU - Tarr, T.

AU - Kocsis, Zsolt

AU - Szegedi, G.

AU - Paragh, G.

PY - 2007/6

Y1 - 2007/6

N2 - Excessive lipid peroxidation is a major factor of accelerated atherosclerosis, observed in patients with systemic lupus erythematosus (SLE). We aimed at the present study to determine the paraoxonase1 (PON1) and arylesterase activities, and lipid-profile in 37 SLE patients and 30 age-/sex-matched controls. Association was analyzed between PON1 activity and SLEDAI, CRP, anti-oxLDL, and antiphospholipid antibody (aPL) levels, steroid dose, and atherothrombotic events. The age of patients was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, SLEDAI 2 (0-15). PON1 and arylesterase activities were measured spectrophotometrically using paraoxon and phenyl acetate as substrates, respectively. Phenotypic distribution of PON1 was determined by dual substrate method. We measured anti-oxLDL and aPL levels by ELISA, the CRP by automated immunoassay. PON1 activity (121.9 ± 65.9 U/mL) was reduced significantly (P <0.001) in SLE as compared to control (188.1 ± 78.9 U/mL), but arylesterase activity was not different. A negative correlation was found between PON1 activity and age. PON1 activity did not correlate with other measured parameters. Reduced PON1 activity associated with clinical atherothrombotic complications (P <0.01). High activity BB phenotypewas not present in SLE. Lipid parameters (TC, LDL-C, HDLC, ApoAI, and ApoB) were within normal range in both groups. Results indicated reduced PON1 activity in lupus patients despite long disease duration and low inflammatory activity, and it was evidenced as a risk for atherosclerotic complications. As the arylesterase activity was normal, further examinations are required to find other mechanisms, such as anti-PON1 antibodies, genetic polymorphisms, and difference in distribution of HDL-subfractions or enzyme abnormalities in HDL remodeling.

AB - Excessive lipid peroxidation is a major factor of accelerated atherosclerosis, observed in patients with systemic lupus erythematosus (SLE). We aimed at the present study to determine the paraoxonase1 (PON1) and arylesterase activities, and lipid-profile in 37 SLE patients and 30 age-/sex-matched controls. Association was analyzed between PON1 activity and SLEDAI, CRP, anti-oxLDL, and antiphospholipid antibody (aPL) levels, steroid dose, and atherothrombotic events. The age of patients was 40.8 ± 13.9 year, follow-up time 6.7 ± 6.2 year, SLEDAI 2 (0-15). PON1 and arylesterase activities were measured spectrophotometrically using paraoxon and phenyl acetate as substrates, respectively. Phenotypic distribution of PON1 was determined by dual substrate method. We measured anti-oxLDL and aPL levels by ELISA, the CRP by automated immunoassay. PON1 activity (121.9 ± 65.9 U/mL) was reduced significantly (P <0.001) in SLE as compared to control (188.1 ± 78.9 U/mL), but arylesterase activity was not different. A negative correlation was found between PON1 activity and age. PON1 activity did not correlate with other measured parameters. Reduced PON1 activity associated with clinical atherothrombotic complications (P <0.01). High activity BB phenotypewas not present in SLE. Lipid parameters (TC, LDL-C, HDLC, ApoAI, and ApoB) were within normal range in both groups. Results indicated reduced PON1 activity in lupus patients despite long disease duration and low inflammatory activity, and it was evidenced as a risk for atherosclerotic complications. As the arylesterase activity was normal, further examinations are required to find other mechanisms, such as anti-PON1 antibodies, genetic polymorphisms, and difference in distribution of HDL-subfractions or enzyme abnormalities in HDL remodeling.

KW - Antioxidant

KW - Atherosclerosis

KW - Paraoxonase1

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=34948901350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948901350&partnerID=8YFLogxK

U2 - 10.1196/annals.1422.009

DO - 10.1196/annals.1422.009

M3 - Conference contribution

C2 - 17893973

AN - SCOPUS:34948901350

SN - 157331708X

SN - 9781573317085

VL - 1108

T3 - Annals of the New York Academy of Sciences

SP - 83

EP - 91

BT - Annals of the New York Academy of Sciences

ER -